Wed, September 5, 2012
Tue, September 4, 2012
Mon, September 3, 2012
Sun, September 2, 2012
Sat, September 1, 2012
Fri, August 31, 2012
Thu, August 30, 2012
Wed, August 29, 2012
Tue, August 28, 2012
Mon, August 27, 2012
Sun, August 26, 2012
Sat, August 25, 2012
Fri, August 24, 2012
Thu, August 23, 2012
Wed, August 22, 2012
[ Wed, Aug 22nd 2012 ] - Market Wire
Inergetics Shareholder Update
Tue, August 21, 2012

Array BioPharma to Present at the Stifel Nicolaus Healthcare, NewsMakers in the Biotech Industry and Morgan Stanley Global Heal


//health-fitness.news-articles.net/content/2012/ .. ech-industry-and-morgan-stanley-global-heal.html
Published in Health and Fitness on Wednesday, August 29th 2012 at 13:16 GMT by Market Wire   Print publication without navigation


BOULDER, Colo.--([ ])--Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the following upcoming conferences. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: [ www.arraybiopharma.com ].

Event:

Stifel Nicolaus Healthcare Conference

Date:

Thursday, September 6, 2012

Time:

9:45 a.m. Eastern Time

Location:

Four Seasons, Boston, MA

Event:

NewsMakers in the Biotech Industry Conference

Date:

Friday, September 7, 2012

Time:

8:30 a.m. Eastern Time

Location:

Millennium Broadway Hotel, New York, NY

Event:

Morgan Stanley Global Healthcare Conference

Date:

Monday, September 10. 2012

Time:

10:35 a.m. Eastern Time

Location:

Grand Hyatt, New York, NY

About Array BioPharma

Array BioPharmaInc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib partnered with AstraZeneca, MEK162 partnered with Novartis, and danoprevir, partnered with InterMune / Roche, having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. For more information on Array, please go to [ www.arraybiopharma.com ].


Publication Contributing Sources